Gain Therapeutics, Inc. (GANX) Earnings History

Gain Therapeutics, Inc. - Q3 2025 Earnings

Filed at: Nov 12, 2025, 4:06 PM EST|Read from source

EXECUTIVE SUMMARY

Gain Therapeutics reported progress in its Phase 1b study for GT-02287 in Parkinson's disease, with early data suggesting a disease-slowing effect and strong participant engagement in study extensions. The company is on track to report further analysis in Q4 2025 and is preparing for Phase 2 development.

POSITIVE HIGHLIGHTS

  • •

    Presented initial Phase 1b data suggesting GT-02287 has a disease-slowing effect, with stabilization and improvement in MDS-UPDRS scores after approximately 30 days.

    positive
  • •

    Completed enrollment of 21 participants in the Phase 1b study, surpassing the original target of 15.

    positive
  • •

    Received Australian approval to extend the Phase 1b study duration, allowing participants to continue treatment for up to 12 months.

    positive
  • •

    Approximately 80% of participants have joined or confirmed interest in the study extension phase, indicating strong engagement.

    positive
  • •

    GT-02287 was generally well tolerated with no treatment-emergent serious adverse events observed.

    positive

CONCERNS & RISKS

  • •

    R&D expenses increased due to ongoing Phase 1b trial costs and unfavorable foreign exchange currency translation.

    attention
  • •

    G&A expenses increased due to higher stock-based compensation, personnel costs, and unfavorable foreign exchange currency translation.

    attention
  • •

    Cash and cash equivalents decreased from $10.4 million at the end of 2024 to $8.8 million as of September 30, 2025.

    attention

FINANCIAL METRICS

Revenue
Quarterly
N/A
N/A
Net Income
Quarterly
N/A
N/A
EPS (Diluted)
Quarterly
$-0.15
+11.8%
Prior year: $-0.17
Annual (YTD)
$-0.50
N/A
Prior year: $-0.78
Operating Income
Quarterly
N/A
N/A
EPS (Basic)
Quarterly
$-0.15
+11.8%
Prior year: $-0.17
Annual (YTD)
$-0.50
N/A
Prior year: $-0.78

MARGIN ANALYSIS

Margin metrics will be available once backend extracts data from insights_json

MANAGEMENT GUIDANCE

FY 2025

IND submission to FDA
"Expected by year end 2025, facilitating expansion into Phase 2 clinical development."

H2 2026

Phase 1b study extension results
"Expected in the second half of 2026."

Q4 2025

functional changes and biomarker activity analysis
"Analysis expected to be available."

Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.

MANAGEMENT COMMENTARY

Encouraged by progress in Q3 2025 and on track to report analysis of functional changes and biomarker activity in Q4 2025.

— Gain Therapeutics, Inc., Q3 2025 2025 Earnings Call

Excited to understand the impact of GT-02287 on Parkinson's disease biology.

— Gain Therapeutics, Inc., Q3 2025 2025 Earnings Call

Early clinical findings suggest GT-02287 has a disease-slowing effect.

— Gain Therapeutics, Inc., Q3 2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

Phase 1b Study Participants Completed 90 Days
16
participants
Phase 1b Study Participants Enrolled
21
participants

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.